Related references
Note: Only part of the references are listed.CFTR interactome mapping using the mammalian membrane two-hybrid high-throughput screening system
Sang Hyun Lim et al.
MOLECULAR SYSTEMS BIOLOGY (2022)
Shining Light on the Dark Side of the Genome
Lori L. Wallrath et al.
CELLS (2022)
Systems Approaches to Unravel Molecular Function: High-content siRNA Screen Identifies TMEM16A Traffic Regulators as Potential Drug Targets for Cystic Fibrosis
Madalena C. Pinto et al.
JOURNAL OF MOLECULAR BIOLOGY (2022)
The dark proteome: translation from noncanonical open reading frames
Bradley W. Wright et al.
TRENDS IN CELL BIOLOGY (2022)
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
Lucile Regard et al.
CELLS (2022)
How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics
Margarida D. Amaral
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
CyFi-MAP: an interactive pathway-based resource for cystic fibrosis
Catarina Pereira et al.
SCIENTIFIC REPORTS (2021)
Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges
Peter J. Barry et al.
CURRENT OPINION IN PULMONARY MEDICINE (2021)
Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease
Matthew D. Strub et al.
GENES (2020)
Proteomics and Metabolomics for Cystic Fibrosis Research
Nara Liessi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
Andrea Gramegna et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue
Rachel A. Hodos et al.
SCIENTIFIC REPORTS (2020)
Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights
Justin E. Ideozu et al.
GENES (2019)
Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
Gert de Wilde et al.
FRONTIERS IN PHARMACOLOGY (2019)
High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
Sylvia Merkert et al.
STEM CELL REPORTS (2019)
Folding Status Is Determinant over Traffic-Competence in Defining CFTR Interactors in the Endoplasmic Reticulum
Joao D. Santos et al.
CELLS (2019)
Exploring the dark genome: implications for precision medicine
Tudor I. Oprea
MAMMALIAN GENOME (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Meta -analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients
Xing Shi et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2019)
Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors
Kenneth A. Giuliano et al.
SLAS DISCOVERY (2018)
The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease
Patrick J. Moore et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue
Lydia A. Perkins et al.
MOLECULAR PHARMACEUTICS (2018)
Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation
Sara Canato et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Cystic fibrosis swine fail to secrete airway surface liquid in response to inhalation of pathogens
Xiaojie Luan et al.
NATURE COMMUNICATIONS (2017)
Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport
Hongyu Li et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Progress in therapies for cystic fibrosis
Kris De Boeck et al.
LANCET RESPIRATORY MEDICINE (2016)
Transcriptome meta-analysis reveals common differential and global gene expression profiles in cystic fibrosis and other respiratory disorders and identifies CFTR regulators
Luka A. Clarke et al.
GENOMICS (2015)
Hallmarks of therapeutic management of the cystic fibrosis functional landscape
Margarida D. Amaral et al.
JOURNAL OF CYSTIC FIBROSIS (2015)
Targeting ion channels in cystic fibrosis
Marcus A. Mall et al.
JOURNAL OF CYSTIC FIBROSIS (2015)
Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients
M. D. Amaral
JOURNAL OF INTERNAL MEDICINE (2015)
Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis
Elisabetta Pesci et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls
Scott C. Bell et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery
Hugo M. Botelho et al.
SCIENTIFIC REPORTS (2015)
Proteomic Analysis of Nasal Epithelial Cells from Cystic Fibrosis Patients
Ludovic Jeanson et al.
PLOS ONE (2014)
Synergy-Based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields ΔF508-CFTR Correctors That Augment VX-809 Maximal Efficacy
Puay-Wah Phuan et al.
MOLECULAR PHARMACOLOGY (2014)
Identification of the SPLUNC1 ENaC- inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures
Carey A. Hobbs et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2013)
High-Content siRNA Screen Reveals Global ENaC Regulators and Potential Cystic Fibrosis Therapy Targets
Joana Almaca et al.
CELL (2013)
Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction
Carlos M. Farinha et al.
CHEMISTRY & BIOLOGY (2013)
Rescuing Mutant CFTR: A Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis
Margarida D. Amaral et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Changes in transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies
Luka A. Clarke et al.
RESPIRATORY RESEARCH (2013)
Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Margarida D. Amaral
CURRENT DRUG TARGETS (2011)
Differential global gene expression in cystic fibrosis nasal and bronchial epithelium
Varrie Ogilvie et al.
GENOMICS (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
In Situ Measurement of Airway Surface Liquid [K+] Using a Ratioable K+-sensitive Fluorescent Dye
Wan Namkung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
High-content Functional Screen to Identify Proteins that Correct F508del-CFTR Function
Agata M. Trzcinska-Daneluti et al.
MOLECULAR & CELLULAR PROTEOMICS (2009)
SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage
Agustin Garcia-Caballero et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis
Margarida D. Amaral et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Correctors of protein trafficking defects identified by a novel high-throughput screening assay
Graeme W. Carlile et al.
CHEMBIOCHEM (2007)
Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms
Monica Roxo-Rosa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease
Jerry M. Wright et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2006)
Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
F Van Goor et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: Search for novel biomarkers of cystic fibrosis lung disease
M Roxo-Rosa et al.
PROTEOMICS (2006)
Therapy through chaperones: Sense or antisense? - Cystic fibrosis as a model disease
MD Amaral
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
New insights into cystic fibrosis: molecular switches that regulate CFTR
William B. Guggino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations
N Pedemonte et al.
MOLECULAR PHARMACOLOGY (2005)
CFTR ΔF508 mutation has minimal effect on the gene expression profile of differentiated human airway epithelia
J Zabner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients
N Bensalem et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening
N Pedemonte et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
The channelopathies: novel insights into molecular and genet mechanisms of human disease
RS Kass
JOURNAL OF CLINICAL INVESTIGATION (2005)
Chloride channel diseases resulting from impaired transepithelial transport or vesicular function
TJ Jentsch et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Inherited disorders of voltage-gated sodium channels
AL George
JOURNAL OF CLINICAL INVESTIGATION (2005)
Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin
CA Farinha et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport
BH Hirth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Drug discovery in academia
AS Verkman
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/ΔF508-CFTR to the plasma membrane
N Davezac et al.
PROTEOMICS (2004)
A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator
MS Gelman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
